The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Phase II study of tosedostat in MDS
Sangmin Lee
• 4 Jun 2021
Sangmin Lee, MD, Weill Cornell Medicine, New York City, NY, gives an update on the Phase II IST-CTI-MDS study (NCT02452346) of tosedostat for patients with myelodysplastic syndromes (MDS). Dr Lee reports that tosedostat monotherapy was found to be active in patients with MDS with an overall response rate of 25% and a median overall survival of 15.6 months. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
